Frederick L Ruberg

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5470279/publications.pdf

Version: 2024-02-01

101 papers	9,470 citations	76326 40 h-index	39675 94 g-index
104 all docs	104 docs citations	104 times ranked	7783 citing authors

#	Article	IF	Citations
1	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 2016, 133, 2404-2412.	1.6	1,335
2	Pericardial Fat, Visceral Abdominal Fat, Cardiovascular Disease Risk Factors, and Vascular Calcification in a Community-Based Sample. Circulation, 2008, 117, 605-613.	1.6	896
3	Transthyretin Amyloid Cardiomyopathy. Journal of the American College of Cardiology, 2019, 73, 2872-2891.	2.8	573
4	Testing of Low-Risk Patients Presenting to the Emergency Department With Chest Pain. Circulation, 2010, 122, 1756-1776.	1.6	545
5	Transthyretin (TTR) Cardiac Amyloidosis. Circulation, 2012, 126, 1286-1300.	1.6	510
6	Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA - Journal of the American Medical Association, 2022, 327, 331.	7.4	434
7	Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation, 2020, 142, e7-e22.	1.6	338
8	Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circulation: Heart Failure, 2019, 12, e006075.	3.9	312
9	Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging. JAMA Cardiology, 2016, 1, 880.	6.1	304
10	Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood, 2011, 118, 4346-4352.	1.4	259
11	Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin. Circulation, 2016, 133, 282-290.	1.6	230
12	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2019, 26, 2065-2123.	2.1	230
13	Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. Trends in Cardiovascular Medicine, 2018, 28, 10-21.	4.9	211
14	Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS). American Heart Journal, 2012, 164, 222-228.e1.	2.7	209
15	Persistent left superior vena cava: a case report and review of literature. Cardiovascular Ultrasound, 2008, 6, 50.	1.6	198
16	Native T1 and Extracellular Volume inÂTransthyretin Amyloidosis. JACC: Cardiovascular Imaging, 2019, 12, 810-819.	5.3	172
17	Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. Journal of Nuclear Cardiology, 2014, 21, 925-939.	2.1	155
18	Diagnostic and Prognostic Utility of Cardiovascular Magnetic Resonance Imaging in Light-Chain Cardiac Amyloidosis. American Journal of Cardiology, 2009, 103, 544-549.	1.6	145

#	Article	IF	Citations
19	Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis. Journal of the American College of Cardiology, 2020, 75, 2851-2862.	2.8	131
20	Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood, 2019, 133, 215-223.	1.4	118
21	Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genetics in Medicine, 2017, 19, 733-742.	2.4	116
22	Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 62-67.	3.0	108
23	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2019, 25, e1-e39.	1.7	107
24	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2â€"Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology, 2020, 27, 659-673.	2.1	97
25	Features of atrial fibrillation in wildâ€type transthyretin cardiac amyloidosis: a systematic review and clinical experience. ESC Heart Failure, 2018, 5, 772-779.	3.1	89
26	Pressure-Volume Relationships in Patients With Transthyretin (ATTR) Cardiac Amyloidosis Secondary to V122I Mutations and Wild-Type Transthyretin. Circulation: Heart Failure, 2011, 4, 121-128.	3.9	84
27	The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis. Journal of Nuclear Cardiology, 2017, 24, 413-424.	2.1	71
28	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Journal of Cardiac Failure, 2019, 25, 854-865.	1.7	70
29	Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. European Heart Journal Cardiovascular Imaging, 2017, 18, 1057-1064.	1.2	60
30	Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Family Practice, 2020, 21, 198.	2.9	60
31	In vivo Detection of Vulnerable Atherosclerotic Plaque by MRI in a Rabbit Model. Circulation: Cardiovascular Imaging, 2010, 3, 323-332.	2.6	57
32	Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis. Journal of Cardiac Failure, 2020, 26, 753-759.	1.7	57
33	Can 99mTc-Pyrophosphate Aid in Early Detection of Cardiac Involvement in Asymptomatic Variant TTR Amyloidosis?. JACC: Cardiovascular Imaging, 2017, 10, 713-714.	5.3	55
34	Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin. Circulation: Heart Failure, 2018, 11, e004000.	3.9	55
35	Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body ¹⁸F-Florbetapir PET/CT. Journal of Nuclear Medicine, 2019, 60, 1234-1239.	5.0	54
36	Adverse Vascular Risk is Related to Cognitive Decline in Older Adults. Journal of Alzheimer's Disease, 2015, 44, 1361-1373.	2.6	49

#	Article	IF	Citations
37	Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model. JAMA Cardiology, 2017, 2, 305.	6.1	48
38	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Circulation: Cardiovascular Imaging, 2021, 14, e000029.	2.6	48
39	The Vanderbilt Memory & Aging Project: Study Design and Baseline Cohort Overview. Journal of Alzheimer's Disease, 2016, 52, 539-559.	2.6	44
40	Myocardial infarction with â€œclean coronariesâ€•caused by amyloid light-chain AL amyloidosis: a case report and literature review. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 160-164.	3.0	42
41	Atherothrombosis: Plaque instability and thrombogenesis. Progress in Cardiovascular Diseases, 2002, 44, 381-394.	3.1	41
42	Improved Quantification of CardiacÂAmyloid Burden in SystemicÂLight ChainÂAmyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 1325-1336.	5.3	41
43	Identification of Atherosclerotic Lipid Deposits by Diffusion-Weighted Imaging. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1440-1446.	2.4	40
44	High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. Blood, 2012, 120, 4445-4446.	1.4	38
45	MRI of Atherothrombosis Associated With Plaque Rupture. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 240-245.	2.4	37
46	The Relationship of Ectopic Lipid Accumulation to Cardiac and Vascular Function in Obesity and Metabolic Syndrome. Obesity, 2010, 18, 1116-1121.	3.0	35
47	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2021, 28, 1769-1774.	2.1	34
48	Light-Chain Amyloidosis With Echocardiographic Features of Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2008, 101, 674-676.	1.6	31
49	Identification of cholesteryl esters in human carotid atherosclerosis by ex vivo image-guided proton MRS. Journal of Lipid Research, 2006, 47, 310-317.	4.2	27
50	Myocardial Lipid Accumulation in the Diabetic Heart. Circulation, 2007, 116, 1110-1112.	1.6	26
51	The influence of pericardial fat upon left ventricular function in obese females: evidence of a site-specific effect. Journal of Cardiovascular Magnetic Resonance, 2014, 16, 37.	3.3	26
52	Establishment of brain natriuretic peptide â€•based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis. British Journal of Haematology, 2020, 188, 424-427.	2.5	25
53	Cardiac Amyloidosis: Multimodal Imaging of Disease Activity and Response to Treatment. Circulation: Cardiovascular Imaging, 2021, 14, e009025.	2.6	24
54	Stroke risk interacts with Alzheimer's disease biomarkers on brain aging outcomes. Neurobiology of Aging, 2015, 36, 2501-2508.	3.1	23

#	Article	IF	Citations
55	Prothrombotic determinants of coronary atherothrombosis. Vascular Medicine, 2002, 7, 289-299.	1.5	21
56	Cardiac Amyloidosis: Evolving Approach to Diagnosis and Management. Current Treatment Options in Cardiovascular Medicine, 2011, 13, 528-542.	0.9	20
57	T1 Mapping in Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2013, 6, 498-500.	5.3	17
58	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Circulation: Cardiovascular Imaging, 2021, 14, e000030.	2.6	16
59	Retinol binding protein 4 (RBP4) concentration identifies V122I transthyretin cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 120-121.	3.0	14
60	A new era of amyloidosis: the trends at a major US referral centre. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 192-196.	3.0	14
61	Quantitative [18F]florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosis. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1998-2009.	6.4	14
62	False Positive 99mTc-Pyrophosphate Scanning Leading to Inappropriate Tafamidis Prescriptions. JACC: Cardiovascular Imaging, 2021, 14, 2042-2044.	5.3	13
63	Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 71-78.	3.0	13
64	Challenging the myths of cardiac amyloidosis. European Heart Journal, 2017, 38, 1909-1912.	2.2	12
65	Predictors of hematologic response and survival with stem cell transplantation in ‹scp›AL‹/scp› amyloidosis: A 25â€year longitudinal study. American Journal of Hematology, 2022, 97, 1189-1199.	4.1	12
66	An Intracardiac Accessory Thyroid Gland. American Journal of Cardiology, 2006, 97, 926-928.	1.6	11
67	ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable. Orphanet Journal of Rare Diseases, 2021, 16, 204.	2.7	11
68	Left Atrial Mechanics Associates With Paroxysmal Atrial Fibrillation in Light-Chain Amyloidosis Following StemÂCell Transplantation. JACC: CardioOncology, 2020, 2, 721-731.	4.0	11
69	Computed Tomography of the Coronary Arteries. Circulation, 2005, 112, .	1.6	10
70	Multiple arterial and venous thromboembolic complications in AL amyloidosis and cardiac involvement: a case report and literature review. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 156-160.	3.0	10
71	Once AL amyloidosis: not always AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 139-140.	3.0	10
72	Nuclear Tracers for Transthyretin Cardiac Amyloidosis. Circulation: Cardiovascular Imaging, 2013, 6, 162-164.	2.6	9

#	Article	IF	Citations
73	Cardiovascular Magnetic Resonance Visualization of Cardiac Amyloid Infiltration. Circulation, 2015, 132, 1525-1527.	1.6	9
74	Prevalence of mutant ATTR cardiac amyloidosis in elderly African Americans with heart failure. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 253-255.	3.0	9
75	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2022, 28, e1-e4.	1.7	8
76	Cardiac Scintigraphy and Screening for Transthyretin Cardiac Amyloidosis. Circulation, 2021, 144, 1005-1007.	1.6	8
77	More Than Meets the Eye: Time for a New Imaging Paradigm to Test for Cardiac Amyloidosis. Journal of Cardiac Failure, 2018, 24, 87-89.	1.7	7
78	Early Diagnosis of Cardiac Amyloidosis by Carpal Tunnel Surgery. Journal of the American College of Cardiology, 2018, 72, 2051-2053.	2.8	7
79	Cardiac Amyloidosis. Circulation: Cardiovascular Imaging, 2017, 10, e006186.	2.6	6
80	Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis. Current Heart Failure Reports, 2019, 16, 180-188.	3.3	6
81	Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy. JACC: Cardiovascular Imaging, 2022, 15, 594-603.	5.3	6
82	Echocardiography and Survival in Light Chain Cardiac Amyloidosis. Circulation: Cardiovascular Imaging, 2018, 11, e007826.	2.6	5
83	Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda. Blood, 2020, 136, 44-45.	1.4	5
84	Imaging Options in Cardiac Amyloidosis: Differentiating AL from ATTR. Current Cardiovascular Imaging Reports, 2017, 10, 1.	0.6	4
85	Familial Amyloid Cardiomyopathy Due to TTR Mutations: An underground Cause of Restrictive Cardiomyopathy. Journal of Cardiac Failure, 2009, 15, 464.	1.7	3
86	Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 165-166.	3.0	3
87	Clinical approach to genetic testing in amyloid cardiomyopathy: from mechanism to effective therapies. Current Opinion in Cardiology, 2021, 36, 309-317.	1.8	3
88	Conduction abnormalities and role of cardiac pacing in cardiac amyloidosis: A systematic review. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 2092-2099.	1.2	3
89	Should Histologic Determination of AmyloidÂLoad Determine Management Decisions in Light-Chain Amyloidosis?. Journal of the American College of Cardiology, 2016, 68, 2493-2494.	2.8	2
90	The importance of SPECT cardiac reconstruction for accurate 99mTc-pyrophosphate interpretation in TTR amyloidosis. Journal of Nuclear Cardiology, 2022, 29, 1478-1480.	2.1	2

#	Article	IF	Citations
91	Abstract 694: More Extensive Left Ventricular Hypertrophy in Transthyretin-Type Cardiac Amyloidosis as Compared to Primary Light-Chain Cardiac Amyloidosis. Circulation, 2008, 118, .	1.6	2
92	Diaphragmatic Motion During Cheyne-Stokes Respiration by Navigator Magnetic Resonance Imaging. Circulation, 2005, 112, e132.	1.6	1
93	Paying at the Pump. Circulation: Cardiovascular Imaging, 2010, 3, 635-637.	2.6	1
94	In Search of the Holy Grail. JACC: Cardiovascular Imaging, 2021, 14, 200-202.	5.3	1
95	The Incidence of Atrial Fibrillation Among Patients with AL Amyloidosis Undergoing High Dose Melphalan and Stem Cell Transplantation (HDM/SCT): Experience at a Single Institution. Blood, 2015, 126, 5490-5490.	1.4	1
96	Phenotype Mapping in CardiacÂAmyloidosis. Journal of the American College of Cardiology, 2021, 78, 2193-2195.	2.8	1
97	Normal Mechanisms of Hemostasis. , 2006, , 61-69.		0
98	Editorâ€™s Note. Circulation: Cardiovascular Imaging, 2017, 10, .	2.6	0
99	Hepatocyte Growth Factor and CardiacÂAmyloidosis. JACC: CardioOncology, 2020, 2, 67-69.	4.0	0
100	Abstract 2397: Morbidity and Mortality of Transthyretin (TTR) Amyloid Cardiomyopathy (ATTR-CM): Transthyretin Amyloidosis Cardiac Study (TRACS) a Prospective Evaluation. Circulation, 2008, 118, .	1.6	0
101	High-Dose Melphalan and Stem Cell Transplantation for Patients with AL Amyloidosis and Cardiac Involvement. Blood, 2011, 118, 2043-2043.	1.4	0